Abstract: Objective :Since the protocol of cytokine -induced killer (CIK) was established by Schmidt Wolf in 1993, the CIK therapy has been mainly used in purge of marrow and treatment of leukemia rather than solid tumors. This study intends to summarize the clinical outcome of 41 patients with solid tumor who received CIK/IL-2 therapy, trying to analyze the role of tumor load in the CIK/IL-2 therapy. Methods : The patients with high-risk recurrence and of advanced stage were recruited. CIK was prepared from autologous PBMCs. CIK combined n-2 was intravenously injected to the patients. Results : During the follow -up from 3 months to 24 months, recurrence occurred in 6 of the 9 cases who subjected to palliative resection. However, recurrence occurred in only 3 of the 14 cases undergoing the radical resection. So the recurrence rate was 66.7Y and 21.4Y respectively (p<0.05). In addition, of the 18 cases with advanced tumor stable patient's condition occurred in 4 cases. Conclusion :The efficacy of CIK/IL-2 therapy is correlated with tumor load. To improve the outcome of CIK/IL-2 therapy i t is recommended to reduce tumor load as far as possible before this treatment.